Latest Period
Q4 2025
Security Snapshot
Forte Biosciences, Inc. - Common Stock (FBRX) Institutional Ownership
CUSIP: 34962G208
13F Institutional Holders and Ownership History from Q3 2024 to Q1 2026
Institutions Reporting
59
Shares (Excl. Options)
11,522,905
Price
$27.27
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock
- Symbol
- FBRX on Nasdaq
- Shares outstanding
- 12,506,886
- Price per share
- $33.90
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 11,522,905
- Total reported value
- $314,510,108
- % of total 13F portfolios
- 0%
- Share change
- +1,950,222
- Value change
- +$55,513,195
- Number of holders
- 59
- Price from insider filings
- $33.90
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- FBRX - Forte Biosciences, Inc. - Common Stock is tracked under CUSIP 34962G208.
- 59 institutions reported positions in Q4 2025.
- 12 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 59 to 4 between Q4 2025 and Q1 2026.
- Reported value moved from $314,510,108 to $2,850,969.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 59 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 34962G208?
CUSIP 34962G208 identifies FBRX - Forte Biosciences, Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 34962G208:
Significant Owners of Forte Biosciences, Inc. - Common Stock (FBRX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FEDERATED HERMES, INC. | 13% | +10% | $18,692,393 | +$1,791,458 | 1,635,380 | +11% | Federated Hermes, Inc. | 30 Sep 2025 |
| ALGER ASSOCIATES INC | 13% | -1.5% | $24,514,005 | +$234,270 | 1,634,267 | +0.96% | Alger Associates, Inc. | 30 Sep 2025 |
| JANUS HENDERSON GROUP PLC | 11% | +15% | $38,881,157 | +$20,950,887 | 1,425,785 | +117% | JANUS HENDERSON GROUP PLC | 31 Dec 2025 |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 10% | 0% | $13,378,307 | +$6,618,184 | 1,268,086 | +98% | TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 30 Jun 2025 |
| Affinity Asset Advisors, LLC | 6.7% | -2.9% | $22,251,791 | -$731,169 | 834,964 | -3.2% | Affinity Asset Advisors, LLC | 22 Jan 2026 |
| Point72 Asset Management, L.P. | 6.3% | $21,132,810 | 792,976 | Point72 Asset Management, L.P. | 12 Jan 2026 | |||
| Ikarian Capital, LLC | 5% | -45% | $6,516,387 | +$89,063 | 617,667 | +1.4% | Ikarian Capital, LLC | 30 Jun 2025 |
| ORBIMED ADVISORS LLC | 8% | $3,763,800 | 510,000 | ORBIMED ADVISORS LLC | 31 Dec 2024 | |||
| Oliveira Steven Michael | 2.4% | -62% | $6,797,265 | -$2,993,786 | 300,100 | -31% | Oliveira Steven Michael | 08 Jan 2026 |
| PERCEPTIVE ADVISORS LLC | 2.5% | $1,209,840 | 163,935 | Perceptive Advisors LLC | 31 Dec 2024 | |||
| BIOTECHNOLOGY VALUE FUND L P | 0.5% | -95% | $980,250 | -$8,674,080 | 65,350 | -90% | BVF PARTNERS L P/IL | 30 Sep 2025 |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.8% | -87% | $567,495 | -$369,187 | 53,791 | -39% | Boothbay Fund Management, LLC | 30 Jun 2025 |
As of 31 Dec 2025, 59 institutional investors reported holding 11,522,905 shares of Forte Biosciences, Inc. - Common Stock (FBRX). This represents 92% of the company’s total 12,506,886 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Forte Biosciences, Inc. - Common Stock (FBRX) together control 89% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FEDERATED HERMES, INC. | 14% | 1,765,516 | +8% | 0.08% | $48,145,621 |
| FRED ALGER MANAGEMENT, LLC | 12% | 1,460,971 | -11% | 0.16% | $39,840,679 |
| JANUS HENDERSON GROUP PLC | 11% | 1,425,785 | +1.6% | 0.02% | $39,159,185 |
| ORBIMED ADVISORS LLC | 9.6% | 1,196,955 | 0% | 0.7% | $32,640,963 |
| Affinity Asset Advisors, LLC | 7.9% | 989,490 | 1.9% | $26,983,392 | |
| VANGUARD GROUP INC | 4.7% | 582,263 | +2.7% | 0% | $15,878,312 |
| Point72 Asset Management, L.P. | 3.9% | 487,275 | 0.02% | $13,287,989 | |
| Cable Car Capital, LP | 3.2% | 400,000 | -20% | 0.68% | $10,908,000 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.7% | 333,333 | 0% | 0.01% | $9,089,991 |
| Woodline Partners LP | 2.7% | 331,987 | 0% | 0.04% | $9,053,285 |
| FMR LLC | 2.5% | 310,965 | +27% | 0% | $8,480,016 |
| Ikarian Capital, LLC | 2.4% | 300,000 | 0% | 1.1% | $8,181,001 |
| MILLENNIUM MANAGEMENT LLC | 2% | 246,685 | +106% | 0% | $6,727,100 |
| AWM Investment Company, Inc. | 1.9% | 236,821 | -9.5% | 0.62% | $6,458,109 |
| Jain Global LLC | 1.6% | 202,433 | 0.05% | $5,520,348 | |
| SPHERA FUNDS MANAGEMENT LTD. | 1.5% | 185,869 | -61% | 1.1% | $5,068,648 |
| AMERIPRISE FINANCIAL INC | 1.2% | 153,027 | +119% | 0% | $4,173,046 |
| GEODE CAPITAL MANAGEMENT, LLC | 1% | 124,609 | +15% | 0% | $3,400,403 |
| MORGAN STANLEY | 0.56% | 70,531 | +46609% | 0% | $1,923,381 |
| GOLDMAN SACHS GROUP INC | 0.54% | 68,023 | 0% | $1,854,987 | |
| BlackRock, Inc. | 0.52% | 64,496 | +27% | 0% | $1,758,806 |
| J. Goldman & Co LP | 0.49% | 60,800 | 0.06% | $1,658,016 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.42% | 52,914 | 0% | $1,442,965 | |
| STATE STREET CORP | 0.41% | 50,721 | +33% | 0% | $1,383,162 |
| 683 Capital Management, LLC | 0.32% | 40,000 | 0.09% | $1,090,800 |
Institutional Holders of Forte Biosciences, Inc. - Common Stock (FBRX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 110,076 | $2,850,969 | +$2,337,873 | $25.90 | 4 |
| 2025 Q4 | 11,522,905 | $314,510,108 | +$55,513,195 | $27.27 | 59 |
| 2025 Q3 | 10,343,866 | $155,080,846 | +$6,727,909 | $15.00 | 42 |
| 2025 Q2 | 9,809,779 | $127,063,335 | +$62,289,077 | $12.93 | 33 |
| 2025 Q1 | 5,034,489 | $39,316,245 | +$4,704,465 | $7.76 | 29 |
| 2024 Q4 | 4,275,821 | $97,104,372 | +$81,936,549 | $22.71 | 26 |
| 2024 Q3 | 736,630 | $4,120,236 | +$4,082,162 | $5.59 | 23 |